Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14750037 | 0.85 | CYP2C9 (0.54) | CYP2C9DGAT1SCN5A | |
| SCHEMBL14749778 | 0.78 | L3MBTL1 (0.44) | CYP2C9DGAT1CNR2SSTR4SSTR1 | |
| SCHEMBL14750029 | 0.73 | CYP2C9 (0.55) | CYP2C9DGAT1 | |
| SCHEMBL21991921 | 0.73 | CYP2C9 (0.75) | CYP2C9HTT | |
| SCHEMBL5366382 | 0.73 | HPGD (0.49) | CYP2C9 | |
| SCHEMBL14750655 | 0.71 | CD69 (0.46) | SCN5AHTT | |
| SCHEMBL13948727 | 0.70 | CYP2C9 (0.46) | CYP2C9DGAT1 | |
| SCHEMBL5367643 | 0.68 | SSTR4 (0.51) | DGAT1SSTR4 | |
| SCHEMBL3881117 | 0.68 | DGAT1 (0.49) | DGAT1HTT | |
| SCHEMBL14750660 | 0.68 | ESR1 (0.48) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | CYP2C9 889/4885DGAT1 942/4885CNR2 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.